Advaxis Inc (ADXS)

4.75
0.02 0.42
NASDAQ : Health Care
Prev Close 4.73
Open 4.72
Day Low/High 4.69 / 4.83
52 Wk Low/High 5.21 / 22.20
Volume 118.05K
Avg Volume 583.30K
Exchange NASDAQ
Shares Outstanding 41.07M
Market Cap 202.45M
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Two Abstracts Featuring Advaxis' Lm-based Candidates Selected For Presentation At The 32nd Annual Society For Immunotherapy Cancer (SITC) Meeting

Two Abstracts Featuring Advaxis' Lm-based Candidates Selected For Presentation At The 32nd Annual Society For Immunotherapy Cancer (SITC) Meeting

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced two abstracts were selected for presentation at...

Advaxis To Present At Cantor Fitzgerald Global Healthcare Conference

Advaxis To Present At Cantor Fitzgerald Global Healthcare Conference

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Anthony Lombardo, interim chief executive officer,...

Relative Strength Alert For Advaxis

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Advaxis Reports Business Update And Third Quarter 2017 Results

Advaxis Reports Business Update And Third Quarter 2017 Results

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today provided a business update and announced its financial...

Advaxis To Present At Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science Into Survival

Advaxis To Present At Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science Into Survival

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced three abstracts were selected for presentation at...

Advaxis Lead Immunotherapy Candidate Continues To Build Recognition Among Industry Leaders

Advaxis Lead Immunotherapy Candidate Continues To Build Recognition Among Industry Leaders

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products based on its proprietary Lm-based antigen delivery system, today...

Advaxis Announces Change In Leadership

Advaxis Announces Change In Leadership

Daniel J. O'Connor, chief executive officer, president and board member of Advaxis, Inc.

Advaxis' Axalimogene Filolisbac Data Selected For Poster Presentation At ESGO 2017

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company developing cancer immunotherapies, today announced that the European Society of Gynaecologic Oncology (ESGO) has accepted an abstract for a poster...

First Week of August 18th Options Trading For Advaxis (ADXS)

Investors in Advaxis Inc saw new options begin trading this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ADXS options chain for the new August 18th contracts and identified the following put contract of particular interest.

Advaxis To Present At 2017 BIO International Convention

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, today announced that Ranya Dajani, Vice President, Business Development, will present a company overview at the 2017...

Advaxis Enters Oversold Territory (ADXS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Advaxis To Be Featured On Worldwide Business With Kathy Ireland®

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, today announced that Advaxis will be featured on Worldwide Business with kathy ireland ® on Sunday, June 18.

Advaxis Details Registrational Trials, EU Regulatory And Commercial Plans At Annual Investor & Analyst Day

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, held its annual Investor & Analyst Day this week with clinical investigators and company leaders providing updates and...

Advaxis To Webcast Investor & Analyst Day 2017

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, today announced that its annual Investor & Analyst Day, scheduled for Monday, June 12, 2017 at 1:00 p.

Update: Webcast Of Advaxis Presentation At Jefferies 2017 Global Healthcare Conference Now Available

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, announced that Daniel J.

Advaxis To Present At Jefferies 2017 Global Healthcare Conference

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, today announced that Daniel J.

Synthetic Genomics Launches CGMP Suite For Pharmaceutical Quality Manufacturing Of Synthetic DNA For Advaxis' Clinical Trials

Customized suite to support Phase 1 study of Advaxis' personalized cancer immunotherapy

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Array BioPharma, Advaxis, Merrimack Pharmaceuticals and Insys Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

Advaxis And Bristol-Myers Squibb Announce Clinical Collaboration To Evaluate ADXS-DUAL And Opdivo (nivolumab) In Metastatic Cervical Cancer

Advaxis, Inc. (NASDAQ:ADXS) and Bristol-Myers Squibb (NYSE:BMY) today announced a clinical development collaboration to evaluate ADXS-DUAL, an investigational immunotherapy targeting HPV-associated cancers, and...

Advaxis To Host Investor & Analyst Day On June 12

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, today announced that it will host its annual Investor & Analyst Day on Monday, June 12, at 1:00 p.

Advaxis Provides Phase 1 Data Of Higher Dose Axalimogene Filolisbac

Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, today published online a poster previously presented at the National Cancer Research Institute (NCRI) Cancer Conference in...

Erin Andrews To Participate In Cervical Cancer Educational Forum Hosted By Sylvester Comprehensive Cancer Center And Gilda's Club, Sponsored By Advaxis

Erin Andrews, host of ABC's Dancing with the Stars, reporter with Fox Sports and cervical cancer survivor, will be a special guest at a forum designed to provide patients and families with an overview of the impact of...

Commit To Buy Advaxis At $7.50, Earn 16.4% Annualized Using Options

Investors eyeing a purchase of Advaxis Inc stock, but tentative about paying the going market price of $8.69/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $7.50 strike, which has a bid at the time of this writing of 90 cents.

Advaxis Recognized As One Of New Jersey's "Best Places To Work 2017"

Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, was named to NJBIZ's 2017 Best Places to Work in New Jersey list, as compiled and ranked by the Best Companies Group (BCG).

Short Interest Moves 13.6% Higher For ADXS

The most recent short interest data has been released for the 03/31/2017 settlement date, which shows a 1,212,760 share increase in total short interest for Advaxis Inc , to 10,115,830, an increase of 13.62% since 03/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.